There is a quality problem in the collection and infusion, and glucose is cheaper than mineral water

Author:Kenji Bureau Time:2022.07.18

Just 20 days after the provincial collection, there was a big deal.

On the evening of July 15th, a notice entitled "Notice on Immediately Immediate Institute of Emergency Control and Implementation of Large -capacity Injection Products produced by Qitaihe Pharmaceutical Factory in Heilongjiang Province" was widely circulated in the industry, and the issuing unit was Heilongjiang Provincial Drug Administration.

The notice shows that because there are visible foreign objects in the 250ml glucose injection product produced by Qitaihe Pharmaceutical Factory in Heilongjiang Province, it is decided to start the province's emergency response to the province's emergencies. Stop all batches of large -capacity injection products in the Qitaihe Pharmaceutical Pharmaceutical Factory, immediately remove the shelves and wait for the recall, and stop using it in clinical practice.

At the same time, it is ordered to stop production immediately, and all batches of inventory products are sealed, statistics, and traceable.

In February this year, Heilongjiang just organized the only basic infusion collection in the country. Jianzhi Bureau learned from authoritative channels: On June 27, Heilongjiang only started the results of the election.

In other words, the Heilongjiang infusion set has only been implemented for less than 20 days, and the selection variety has serious quality problems.

In January 2021, Premier Li Keqiang made it clear at the executive meeting of the State Council that the procurement and use of drugs seemed to be procurement and used, but the incident benefited hundreds of millions of patients, which was actually a big reform. Elected enterprises should ensure that drugs are reduced without lowering quality and no efficacy.

However, in addition to Heilongjiang, recent national collection has also been eligible for quality problems.

The winning price is less than 1.21 yuan

Not as good as a bottle of mineral water

The infusion is a product that is directly injected into the human body. There is an irreplaceable visible foreign body that is a serious quality problem, which may lead to the consequences of human local blockage, tissue hypoxia, veinitis, edema, and edema.

At present, the official survey results have not been given, and the outside world cannot know why the product is visible.

A series of measures currently carried out by Heilongjiang shows that the provincial pharmaceutical regulatory department attaches great importance to this risk and is fully controlling the spread of risks.

Large infusion is not a "frequent visitor" of collection. As early as 10 years ago, there was a saying that "a bottle of infusion is not as expensive as a bottle of mineral water." The collection of nationals and provinces and cities is generally aimed at a variety of clinical dosage. Basic infusion has been included in the collection in some provinces, but it is not common.

When Heilongjiang organized a special large infusion set, many companies felt suddenly. In the principle of selection established by Heilongjiang, the price factors account for 70%. In order to stay in the hospital market, many pharmaceutical companies must make every effort to reduce prices in exchange for living space.

The selected varieties of the Qitaihe Pharmaceutical Factory involved are glucose injection, which is one of the main varieties of Heilongjiang's large infusion collection. There are many large infusion specifications. The final quotation result is that the maximum quotation of 100ml (10%) upright soft bag glucose injection is 3.92 yuan per bag, and the cheapest 100ml (5%) plastic bottle is only 0.65 yuan per bottle.

The final price selection decreased by 32.4%from the previous year.

Two varieties were selected in Qitaihe Pharmaceutical Factory: 250ml (5%) non -upright soft bag glucose injection and 250ml (0.9%) non -upright soft bag sodium chloride injection. It is the previous one who has a problem.

The official price of the 250ml bag of glucose injection has not been announced, but according to the maximum effective declaration price of 1.2 yuan per bag, the price of the Qitaihe Pharmaceutical Pharmaceutical Pharmaceutical Factory is definitely cheaper than the equivalent mineral water.

The Jianzhi Bureau also found that most of the companies in this collection of bids are local pharmaceutical companies in Heilongjiang. In addition to Qitaihe Pharmaceutical Factory, there are Harbin Sanlian Pharmaceutical Co., Ltd. and Heilongjiang Boyu Pharmaceutical Co., Ltd..

People familiar with the matter explained to the Jianxian Bureau: "The volume of infusion is large and heavy, and the delivery cost is high. Such low prices must achieve stable supply in the province, and there is no chance of enterprises outside the province."

Analysts pointed out that the price of large infusion products is relatively limited. If the "low price win", I am afraid that it will affect the actual production and distribution business of the enterprise. After all Essence

Low price requires companies more cautious

Provincial collection of collection will become the focus of inspection

Big infusion does not make money, which is what you know in the industry.

China Resources Double Crane is a domestic infusion leader. The company's financial reports are divided into the allocation costs of the two major blocks of infusion and non -infusion, which can give people a glimpse of the real profit level of the infusion industry.

In 2021, the gross profit margin of Shuanghe's infusion business was 49.21%, which seemed not low. However, if the sales expenses and management costs are left, the profit margin will be rapidly dropped to 12.7%. In addition to various hidden costs, the actual profit margin of the infusion factory is very low.

Heilongjiang sets the highest effective declaration price of 1.21 yuan per bag. It does not have the price of a bottle of mineral water. If the company wants to choose, it must have more detailed planning in the overall operation. If a risk point is not controlled, there may be such a thing like Qitaihe Pharmaceutical Factory. Once clinical safety issues occur, they will lose money.

But the price is low, not the reason for the quality of the product.

Chen Jinfu, deputy director of the National Medical Insurance Bureau, made it clear: "We do not pursue the lowest price and insist on opposing running bidding."

In fact, the accident is not only the infusion, but also the local collection.

On June 29, the Shanghai Drug Administration issued a notice that some batch products "dry weight" projects produced by the Indian Sun Company did not meet the registration standards for imported drugs and were canceled the fifth batch of national drug collection mining Election qualifications.

Indian companies participating in my country's collection, how to control the cost of production for the time being unknown. However, it can be confirmed that with the enlightenment of the collection of various places, can the principle of "low -priced winning bid" make companies earn reasonable profits? The industry does feel difficult. Earlier, well -known pharmaceutical companies such as Shi Guibao, Yam Dex, North China Pharmaceutical, Baiyunshan all appeared. Analysts pointed out that the above -mentioned pharmaceutical companies are helpless. The reason for the reason is that the production capacity is insufficient or the price is too low.

However, the State Medical Insurance Bureau has established a credit evaluation system. If any illegal situation of pharmaceutical companies will be included in the "illegal list", it has suspended the company's collection qualification for a period of time, and has suffered severe punishment for losing the market.

This time, the Heilongjiang Pharmaceutical Bureau discovered that there were visible foreign objects in the collection of varieties, and the manufacturers were dealt with several measures such as removal, recall, and discontinuation of production to control the spread of quality risks. Such a response speed has been widely praised in the industry.

The Jianzhi Bureau noticed that Ji Cai also continued to amend the rules of winning the bid, and considered multi -dimensional such as price, quality, supply and clinical demand.

Although the national collection has been gradually standardized, the provincial collection and cross -regional procurement alliances still need to explore more. Analysts pointed out that the collection of drugs is not the only low price, and it does not encourage corporate vicious competition, regardless of cost over competition, making price competition more reasonable, so that ordinary people can truly use drugs and consumables with better quality prices.

Writing ｜ Lei Gong